Codexis, Takeda expand gene therapy collaboration

By The Science Advisory Board staff writers

June 10, 2021 -- Codexis has expanded its strategic collaboration and license agreement with Takeda Pharmaceutical for the research and development of an additional gene therapy for a lysosomal storage disorder, bringing the total number of programs under the agreement to four.

Under the original agreement, Codexis used its CodeEvolver protein engineering platform to generate novel gene sequences that encode enzyme variants with enhanced efficacy. Subsequently, Takeda has combined the improved transgenes with its gene therapy capabilities to develop novel candidates for the treatment of rare genetic disorders.

Takeda had the contractual option to expand the collaboration into a fourth program. Codexis is responsible for the creation of novel enzyme sequences for advancement as gene therapies into preclinical development.

Takeda is responsible for the preclinical and clinical development and commercialization of gene therapy products resulting from the collaboration programs. Codexis is eligible to receive an upfront payment, reimbursement for research and development fees, development and commercial milestone payments, and royalties in the low- to mid-single-digits on sales of any commercial products developed through the program.

Copyright © 2021
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for

Already have an account? Sign in here